Pfizer says once-a-month weight-loss drug works as it forecasts profit decline

Core Insights - Pfizer announced a positive study outcome for a weight-loss drug candidate, indicating potential growth in this therapeutic area [1] - The company also projected a decline in profits, attributing this to the pricing and tariff policies implemented during the Trump administration [1] Group 1: Drug Development - Pfizer's weight-loss drug candidate has shown promising results in a recent study, which could enhance its portfolio in the obesity treatment market [1] Group 2: Financial Outlook - The company forecasts a profit decline, highlighting the adverse effects of the Trump administration's policies on drug pricing and tariffs [1]